This is a routine insider sale tied to option exercise and compensation, not a strategic exit. Monitor for any pattern of larger insider sales or changes in executive holdings in future Form 4 filings.
TEVA drugs
TEVA drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 10 $42.40entry
- T+1 · 6d ago +1.98%α +0.66% · $43.24
- T+4 · todayOpen
- T+5 · in 8h Pending
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Richard Daniell, Executive VP European Commercial at Teva, filed a Form 144 notice of intent to sell 25,000 ordinary shares with an approximate market value of $1,072,789. The sale is tied to a stock option exercise and compensation, with the proposed sale date of November 9, 2026. This is a routine insider sale by a senior executive, not the CEO or CFO, and represents a small fraction of the company's $48.7B market cap.
Key Facts
- Insider Richard Daniell (Executive VP European Commercial) filed Form 144 to sell 25,000 ordinary shares
- Approximate sale value: $1,072,789.40 based on indicative market price of $42.911576 per share
- Sale is related to a stock option exercise and compensation
- Proposed sale date: November 9, 2026
- Broker: Citigroup Global Markets Inc.
- Shares to be sold represent about 0.002% of Teva's $48.7B market cap
Financial Impact
Sale of 25,000 shares valued at approximately $1.07M, a small fraction of the insider's likely holdings and negligible relative to Teva's market cap
Risk Factors
- Insider sale may signal reduced conviction, though the amount is small relative to total holdings
- Form 144 is an intent to sell; the actual sale may not occur
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001973379-26-000365 |
| Document: 0001973379-26-000365-index.html | 0001973379-26-000365 |
| Document: 0001973379-26-000365.txt | 0001973379-26-000365 |
Track record
61 reports on TEVA
6 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +33.06% at T+60 after the Jul 20, 2026 report. 15 of 17 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $43.16 Now $42.57 −1.37% settles Feb 12
- Nov 12, 20264d ago 3 Neutral 2/10 Entry $44.50 Now $42.57 −4.34% settles Feb 11
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $44.50 Now $42.57 −4.34% settles Feb 11
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $43.65 Now $42.57 −2.47% settles Feb 10
- Nov 10, 20266d ago 144 Neutral 3/10 Entry $43.24 Now $42.57 −1.55% settles Feb 9
- Nov 10, 20266d ago SC 13G/A Neutral 3/10 Entry $42.40 Now $42.57 +0.40% settles Feb 8
- Nov 9, 20267d ago 144 Neutral 2/10 Viewing Entry $42.40 Now $42.57 +0.40% settles Feb 8
- Nov 6, 202610d ago Insider Cluster Neutral 3/10 Entry $42.97 Now $42.57 −0.93% settles Feb 5
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $42.97 Now $42.57 −0.93% settles Feb 5
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $42.61 Now $42.57 −0.09% settles Feb 4
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers